Shares of Agios Pharmaceuticals AGIO were unchanged after the company reported Q3 results.
Quarterly Results
Earnings per share were up 20.99% over the past year to ($1.43), which missed the estimate of ($1.38).
Revenue of $34,706,000 higher by 33.36% year over year, which missed the estimate of $38,020,000.
Looking Ahead
Agios Pharmaceuticals hasn't issued any earnings guidance for the time being.
Agios Pharmaceuticals hasn't issued any revenue guidance for the time being.
Conference Call Details
Date: Nov 05, 2020
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/wf6ni9pt
Recent Stock Performance
52-week high: $56.74
52-week low: $27.77
Price action over last quarter: down 8.38%
Company Profile
Agios Pharmaceuticals Inc is a biopharmaceutical company with a focus on developing treatments geared towards cancer and rare genetic disorders of metabolism. The company's primary focus is to develop potentially transformative small-molecule medicines. The clinical development strategy for Agios' product candidates includes a precision approach with initial study designs that allow for genetically or biomarker-defined patient populations. The company seeks the potential for proof of concept early in clinical development, along with any potential for accelerated approval.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
